Age class | Vaccine efficacya | Reference | Vaccination coverage | Reference (initial value) | |||
---|---|---|---|---|---|---|---|
Scenario 1 | Scenario 2 | ||||||
TIV | LAIV | TIV | TIV | LAIV | |||
1 year | 11.0% | N/A | Vesikari et al. [41] | 19.2% | 19.2% | --- | Blank et al. [30] |
2 years | 59.0% | 80.0% | 19.2% | 19.2% | 22.4-50%b | Blank et al. [30] | |
3-6 years | 59.0% | 80.0% | 22.4% | N/A | 22.4-50%b | Blank et al. [30] | |
7-10 years | 59.0% | 80.0% | 23.6% | N/A | 23.6-50%b | Blank et al. [30] | |
11-17 years | 59.0% | 80.0% | 11.0% | N/A | 11.0-50%b | Blank et al. [30] | |
18-59 years, normal risk | 68.0% | N/A | Monto et al. [29] | 14.5% | 14.5% | N/A | Blank et al. [30] |
18-59 years, elevated risk | 58.0% | N/A | Jefferson et al. [28] | 29.8% | 29.8% | N/A | Blank et al. [31] |
60-64 years | 58.0% | N/A | Jefferson et al. [28] | 33.1% | 33.1% | N/A | Blank et al. [31] |
65-69 years | 58.0% | N/A | Jefferson et al. [28] | 47.6% | 47.6% | N/A | Blank et al. [31] |
70 years and over | 58.0% | N/A | Jefferson et al. [28] | 53.4% | 53.4% | N/A | Blank et al. [31] |